Fibroblasts weaken the anti-tumor effect of gefitinib on co-cultured non-small cell lung cancer cells

Chinese Medical Journal

Volumn 127, Issue 11, 2014, Pages 2091-2096

  Yong, Xiao ^a   Wang, Pei Qin ^b   Jiang, Tao ^c   Yu, Wen Chen ^c   Shang, Yan ^a   Han, Yi Ping ^a   Zhang, Ping Ping ^b   Li, Qiang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c QINGDAO UNIVERSITY   (China)

Author keywords

Cancer associated fibroblasts; Co culture; Epithelial mesenchymal transition; Gefitinib; Lung cancer; Proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; GEFITINIB; QUINAZOLINE DERIVATIVE;

CELL PROLIFERATION; COCULTURE; CYTOLOGY; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; HUMAN; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROBLASTS; HUMANS; LUNG NEOPLASMS; QUINAZOLINES;

EID: 84901649637     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20133050     Document Type: Article

References (28)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Ji XD, Li G, Feng YX, Zhao JS, Li JJ, Sun ZJ, et al. EphB3 is over expressed in non-small-cell lung cancer and promotes tumor metastasis by enhancing cell survival and migration. Cancer Res 2011; 71: 1156-1166.
3. Wood SL, Pernemalm M, Crosbie PA, Whetton AD. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev 2014; 40: 558-566.
4. Camelliti P, Borg TK, Kohl P. Structural and functional characterization of cardiac fbroblasts. Cardiovasc Res 2005; 65: 40-51.
5. Tokunou M, Niki T, Eguchi K, Iba S, Tsuda H, Yamada T, et al. C-MET expression in myofbroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma. Am J Pathol 2001; 158: 1451-1463.
6. Nagy JA, Brown LF, Senger DR, Lanir N, Van de Water L, Dvorak AM, et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 1989; 948: 305-326.
7. Foroni C, Broggini M, Generali D, Damia G. Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat Rev 2012; 38: 689-697.
8. Laberge RM, Awad P, Campisi J, Desprez PY. Epithelial-mesenchymal transition induced by senescent fbroblasts. Cancer Microenviron 2012; 5: 39-44.
9. Marijon H, Dokmak S, Paradis V, Zappa M, Bieche I, Bouattour M, et al. Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma. J Hepatol 2011; 54: 1073-1078.
10. Lee DH, Han JY, Lee HG, Lee JJ, Lee EK, Kim HY, et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 2005; 11: 3032-3037.
11. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-2799.
12. Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 2003; 63: 5054-5059.
13. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer Statistics, 2001. CA Cancer J Clin 2001; 51: 15-36.
14. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW. The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 2002; 70: 537-546.
15. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006; 1: 119-150.
16. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
17. Bourguignon LY, Gilad E, Peyrollier K. Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration. J Biol Chem 2007; 282: 19426-19441.
18. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 2002; 16: 3074-3086.
19. Coussens LM, Werb Z. Infammation and cancer. Nature 2002; 420: 860-867.
20. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
21. Tian M, Neil JR, Schiemann WP. Transforming growth factor-beta and the hallmarks of cancer. Cell Signal 2011; 23: 951-962.
22. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 2003; 89: 1270-1275.
23. Fang J, Shing Y, Wiederschain D, Yan L, Butterfeld C, Jackson G, et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A 2000; 97: 3884-3889.
24. Hiraoka N, Allen E, Apel IJ, Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fbrinolysins. Cell 1998; 95: 365-377.
25. Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 2005; 7: 436-451.
26. Chao DL, Sanchez CA, Galipeau PC, Blount PL, Paulson TG, Cowan DS, et al. Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study. Clin Cancer Res 2008; 14: 6988-6995.
27. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to Gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
28. Strauss L, Volland D, Guerrero A, Reichert T. Antiangiogenic and anti-immunosuppressive therapeutic strategies in human head and neck squamous cell carcinoma (HNSCC). Mund Kiefer Gesichtschir 2005; 9: 273-281.